ArticleERJ open research2026
Pulmonary function in young childhood cancer survivors: results from a prospective multicentre cohort.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Childhood cancer survivors (CCSs) are at risk of pulmonary late effects, but post-treatment lung function remains understudied. Current guidelines recommend screening only for symptomatic survivors treated with lung-damaging treatments. We evaluated pulmonary function, risk factors and respiratory symptoms in a representative paediatric CCS cohort, including those with standard treatments. Methods: In this prospective multicentre study, we included CCSs aged 6-21 years, stratified as high-risk (thoracic radiotherapy/surgery, busulfan/bleomycin/nitrosourea chemotherapy and haematopoietic stem cell transplantation (HSCT)) or standard-risk (other systemic treatment). Pulmonary function was assessed Results: With a response rate of 90%, 251 CCSs participated (median 7 years post-diagnosis). Mean z-scores for FEV Conclusion: Pulmonary function was mostly normal in standard-risk CCSs, whereas high-risk survivors showed mild reductions, often asymptomatic. These findings support targeted surveillance based on treatment exposure rather than symptoms to guide long-term care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.